Rise in prevalence of infectious and chronic diseases is a prominent factor boosting the global diagnostic specialty antibodies market growth. Diagnostic biomarker antibodies are broadly used in the diagnosis of chronic and infectious diseases.
They can also be effectively used in the detection of pregnancy and monitoring the action of drugs in the body. Advancements in DNA-based technologies and diagnostics are also augmenting the diagnostic specialty antibodies market size.
Companies operating in the global diagnostic specialty antibodies are exploring the process of quantification of protein abundance on single cells by using split-pool sequencing on DNA-barcoded antibodies for various diagnostic applications.
In line with the latest diagnostic specialty antibodies market trends, they are further exploring the usage of biosensors, which are efficient than polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA).
Antibody refers to a blood protein produced as a response to a specific antigen. Advancements in recombinant DNA technology have facilitated the creation of diagnostic specialty antibodies that are used in imaging and therapeutic applications. Diagnostic specialty antibodies are also used in general medical practice.
Increase in prevalence of infectious and chronic diseases is driving the demand for diagnostic kits and biological drugs. Several biopharmaceutical and biotechnology companies are offering in-vitro diagnostics antibodies to cater to the requirements of the immunoassay reagents market.
However, certain variables are likely to negatively influence the future analysis and development trends in diagnostic specialty antibodies market.
One of these pertains to the quantity of antibody that needs to be present in body fluids or blood. Any discrepancy in this quantity may give incorrect results. This is anticipated to hamper the growth of the diagnostic specialty antibodies industry during the forecast period.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
As per the National Institutes of Health, out of the population aged 50 and above across the globe, the percentage with minimum one chronic disease is expected to increase by 99.5% between 2020 and 2050.
The National Institutes of Health further states that the percentage of people suffering from multimorbidity is estimated to rise to 91.2% between 2020 and 2050.
Infectious diseases are also proving to be one of the major threats to health. The recent examples include SARS, Ebola virus, and AIDS.
Diagnostic specialty antibodies enable the identification of emerging disease hotspots. This helps in ascertaining health risks at an earlier stage and preparing containment strategies pertaining to these risks.
Of late, re-emergence of certain diseases is being observed due to the acquired resistance of pathogens to antimicrobial medications such as antibiotics. Rise in need to exercise control over infectious and chronic diseases is a key factor that is bolstering the diagnostic specialty antibodies industry.
According to an article published by BMC Public Health, a scientific journal published by BioMed Central, immunohistochemistry (IHC) using polyclonal and monoclonal antibodies is useful to detect pathogen antigens in fixed tissues.
As per BMC Public Health, this complements the direct diagnosis of infectious diseases by PCR and culture on fresh tissues. Immunohistochemistry technique that uses anti-p24 monoclonal antibody is also proving useful in detection of HIV in lymph node biopsies of patients suffering from follicular hyperplasia.
As per an article published in April 2021 by Multidisciplinary Digital Publishing Institute (MDPI), a publisher of open-access scientific journals, monoclonal antibodies are among the emerging tools used for the diagnosis of cancer.
Researchers have recently cloned an anti-p16 antibody that may turn out to be a novel valuable tool for diagnosing pathological cancer.
In October 2022, Roche announced the launch of Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody for identifying PRAME protein expression in tissue samples from those suffering from melanoma. PRAME antibody is used to differentiate between malignant and benign lesions.
Thus, continuous advancements in DNA-based technologies is accelerating the demand for next-generation antibodies for multiplexed diagnostic panels.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America accounted for the largest diagnostic specialty antibodies market share in 2022. The region is projected to maintain its leading position across the globe during the forecast period.
Market expansion in North America can be ascribed to the presence of a well-established healthcare infrastructure in the U.S. Furthermore, the country witnessed 1.9 million new cases of cancer in 2021 alone. This is also fostering market development in the region.
Europe and Asia Pacific are projected to record considerable market progress in the near future owing to the rise in awareness about need for specialized antibodies for neurological disorder diagnostics. As per the National Institutes of Health, stroke, headache, and dementia are rampant in the European Union.
Companies operating in the global diagnostic specialty antibodies landscape are engaged in mergers and acquisitions to strengthen their industry position.
In October 2022, Thermo Fisher announced that it had signed a definitive agreement to acquire The Binding Site Group with the objective of improving diagnosis as well as management of immune system disorders and blood cancers.
Abcam plc, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Sanofi, Bio-Rad Laboratories, Inc., Boehringer Ingelheim International GmbH, Agilent Technologies, Inc., and Aytu BioScience, Inc. have been profiled in the diagnostic specialty antibodies market analysis report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 26.1 Bn |
| Market Forecast (Value) in 2031 | US$ 41.4 Bn |
| Growth Rate (CAGR) | 5.4% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 26.1 Bn in 2022
It is projected to grow at a CAGR of 5.4% from 2023 to 2031
Increase in incidence of chronic and infectious diseases, and advancements in DNA-based technologies and diagnostics
The hospitals segment accounted for the largest share in 2022
North America was the dominant region in 2022
Abcam plc, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Sanofi, Bio-Rad Laboratories, Inc., Boehringer Ingelheim International GmbH, Agilent Technologies, Inc., and Aytu BioScience, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Diagnostic Specialty Antibodies Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Diagnostic Specialty Antibodies Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Diagnostic Specialty Antibodies Market Analysis and Forecast, by Antibody Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Antibody Type, 2017-2031
6.3.1. Monoclonal Antibodies
6.3.2. Polyclonal Antibodies
6.3.3. Recombinant Polyclonal Antibodies
6.4. Market Attractiveness Analysis, by Antibody Type
7. Global Diagnostic Specialty Antibodies Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Hepatitis Diagnosis
7.3.2. Tuberculosis Diagnosis
7.3.3. Dengue Diagnosis
7.3.4. Oncology Diagnosis
7.3.5. HIV Diagnosis
7.3.6. Infectious Disease Diagnosis
7.3.7. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Diagnostic Specialty Antibodies Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Diagnostic Specialty Antibodies Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Diagnostic Specialty Antibodies Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Antibody Type, 2017-2031
10.3.1. Monoclonal Antibodies
10.3.2. Polyclonal Antibodies
10.3.3. Recombinant Polyclonal Antibodies
10.4. Market Value Forecast, by Application, 2017-2031
10.4.1. Hepatitis Diagnosis
10.4.2. Tuberculosis Diagnosis
10.4.3. Dengue Diagnosis
10.4.4. Oncology Diagnosis
10.4.5. HIV Diagnosis
10.4.6. Infectious Disease Diagnosis
10.4.7. Others
10.5. Market Value Forecast, by End-user, 2017-2031
10.5.1. Hospitals
10.5.2. Diagnostic Laboratories
10.5.3. Others
10.6. Market Value Forecast, by Country, 2017-2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Antibody Type
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Diagnostic Specialty Antibodies Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Antibody Type, 2017-2031
11.3.1. Monoclonal Antibodies
11.3.2. Polyclonal Antibodies
11.3.3. Recombinant Polyclonal Antibodies
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Hepatitis Diagnosis
11.4.2. Tuberculosis Diagnosis
11.4.3. Dengue Diagnosis
11.4.4. Oncology Diagnosis
11.4.5. HIV Diagnosis
11.4.6. Infectious Disease Diagnosis
11.4.7. Others
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Diagnostic Laboratories
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Antibody Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Diagnostic Specialty Antibodies Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Antibody Type, 2017-2031
12.3.1. Monoclonal Antibodies
12.3.2. Polyclonal Antibodies
12.3.3. Recombinant Polyclonal Antibodies
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Hepatitis Diagnosis
12.4.2. Tuberculosis Diagnosis
12.4.3. Dengue Diagnosis
12.4.4. Oncology Diagnosis
12.4.5. HIV Diagnosis
12.4.6. Infectious Disease Diagnosis
12.4.7. Others
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Diagnostic Laboratories
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Antibody Type
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Diagnostic Specialty Antibodies Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Antibody Type, 2017-2031
13.3.1. Monoclonal Antibodies
13.3.2. Polyclonal Antibodies
13.3.3. Recombinant Polyclonal Antibodies
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Hepatitis Diagnosis
13.4.2. Tuberculosis Diagnosis
13.4.3. Dengue Diagnosis
13.4.4. Oncology Diagnosis
13.4.5. HIV Diagnosis
13.4.6. Infectious Disease Diagnosis
13.4.7. Others
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Diagnostic Laboratories
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Antibody Type
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Diagnostic Specialty Antibodies Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Antibody Type, 2017-2031
14.3.1. Monoclonal Antibodies
14.3.2. Polyclonal Antibodies
14.3.3. Recombinant Polyclonal Antibodies
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Hepatitis Diagnosis
14.4.2. Tuberculosis Diagnosis
14.4.3. Dengue Diagnosis
14.4.4. Oncology Diagnosis
14.4.5. HIV Diagnosis
14.4.6. Infectious Disease Diagnosis
14.4.7. Others
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Diagnostic Laboratories
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Antibody Type
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Abcam plc
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. F. Hoffmann-La Roche Ltd.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Abbott Laboratories
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Bio-Rad laboratories, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Boehringer Ingelheim International GmbH
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Agilent Technologies, Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Aytu BioScience, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
List of Tables
Table 01: Global Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Antibody Type, 2017-2031
Table 02: Global Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 03: Global Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 04: Global Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Antibody Type, 2017-2031
Table 07: North America Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 08: North America Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 09: Europe Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Antibody Type, 2017-2031
Table 11: Europe Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 12: Europe Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 13: Asia Pacific Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Antibody Type, 2017-2031
Table 15: Asia Pacific Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 16: Asia Pacific Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 17: Latin America Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Antibody Type, 2017-2031
Table 19: Latin America Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 20: Latin America Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Middle East & Africa Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Antibody Type, 2017-2031
Table 23: Middle East & Africa Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 24: Middle East & Africa Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Diagnostic Specialty Antibodies Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Diagnostic Specialty Antibodies Market Revenue (US$ Mn), by Antibody Type, 2022
Figure 03: Global Diagnostic Specialty Antibodies Market Value Share, by Antibody Type, 2022
Figure 04: Global Diagnostic Specialty Antibodies Market Revenue (US$ Mn), by Application, 2022
Figure 05: Global Diagnostic Specialty Antibodies Market Value Share, by Application, 2022
Figure 06: Global Diagnostic Specialty Antibodies Market Revenue (US$ Mn), by End-user, 2022
Figure 07: Global Diagnostic Specialty Antibodies Market Value Share, by End-user, 2022
Figure 08: Global Diagnostic Specialty Antibodies Market Value Share, by Region, 2022
Figure 09: Global Diagnostic Specialty Antibodies Market Value (US$ Mn) Forecast, 2023-2031
Figure 10: Global Diagnostic Specialty Antibodies Market Value Share Analysis, by Antibody Type, 2022 and 2031
Figure 11: Global Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Antibody Type, 2023-2031
Figure 12: Global Diagnostic Specialty Antibodies Market Value Share Analysis, by Application, 2022 and 2031
Figure 13: Global Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Application, 2023-2031
Figure 14: Global Diagnostic Specialty Antibodies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 15: Global Diagnostic Specialty Antibodies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 16: Global Diagnostic Specialty Antibodies Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Diagnostic Specialty Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 19: North America Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Country, 2023-2031
Figure 20: North America Diagnostic Specialty Antibodies Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Diagnostic Specialty Antibodies Market Value Share Analysis, by Antibody Type, 2022 and 2031
Figure 22: North America Diagnostic Specialty Antibodies Market Value Share Analysis, by Application, 2022 and 2031
Figure 23: North America Diagnostic Specialty Antibodies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 24: North America Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Antibody Type, 2023-2031
Figure 25: North America Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Application, 2023-2031
Figure 26: North America Diagnostic Specialty Antibodies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 27: Europe Diagnostic Specialty Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 28: Europe Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 29: Europe Diagnostic Specialty Antibodies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Diagnostic Specialty Antibodies Market Value Share Analysis, by Antibody Type, 2022 and 2031
Figure 31: Europe Diagnostic Specialty Antibodies Market Value Share Analysis, by Application, 2022 and 2031
Figure 32: Europe Diagnostic Specialty Antibodies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 33: Europe Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Antibody Type, 2023-2031
Figure 34: Europe Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Application, 2023-2031
Figure 35: Europe Diagnostic Specialty Antibodies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 36: Asia Pacific Diagnostic Specialty Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 37: Asia Pacific Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Asia Pacific Diagnostic Specialty Antibodies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Diagnostic Specialty Antibodies Market Value Share Analysis, by Antibody Type, 2022 and 2031
Figure 40: Asia Pacific Diagnostic Specialty Antibodies Market Value Share Analysis, by Application, 2022 and 2031
Figure 41: Asia Pacific Diagnostic Specialty Antibodies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 42: Asia Pacific Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Antibody Type, 2023-2031
Figure 43: Asia Pacific Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Application, 2023-2031
Figure 44: Asia Pacific Diagnostic Specialty Antibodies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 45: Latin America Diagnostic Specialty Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 46: Latin America Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 47: Latin America Diagnostic Specialty Antibodies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Diagnostic Specialty Antibodies Market Value Share Analysis, by Antibody Type, 2022 and 2031
Figure 49: Latin America Diagnostic Specialty Antibodies Market Value Share Analysis, by Application, 2022 and 2031
Figure 50: Latin America Diagnostic Specialty Antibodies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 51: Latin America Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Antibody Type, 2023-2031
Figure 52: Latin America Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Application, 2023-2031
Figure 53: Latin America Diagnostic Specialty Antibodies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 54: Middle East & Africa Diagnostic Specialty Antibodies Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 55: Middle East & Africa Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 56: Middle East & Africa Diagnostic Specialty Antibodies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Diagnostic Specialty Antibodies Market Value Share Analysis, by Antibody Type, 2022 and 2031
Figure 58: Middle East & Africa Diagnostic Specialty Antibodies Market Value Share Analysis, by Application, 2022 and 2031
Figure 59: Middle East & Africa Diagnostic Specialty Antibodies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 60: Middle East & Africa Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Antibody Type, 2023-2031
Figure 61: Middle East & Africa Diagnostic Specialty Antibodies Market Attractiveness Analysis, by Application, 2023-2031
Figure 62: Middle East & Africa Diagnostic Specialty Antibodies Market Attractiveness Analysis, by End-user, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Diagnostic Specialty Antibodies Market
